Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People whose prostate cancer has been confirmed by a pathology test and diagnosed as prostate adenocarcinoma (a specific type of prostate cancer)
- People whose cancer is graded as ISUP grade 1, 2, or 3 (a scale used to describe how the cancer cells look under a microscope)
- People with ISUP grade 3 cancer where the cancer has not spread to nearby lymph nodes or other parts of the body (for newly diagnosed patients, this must have been confirmed by scans within the last 6 months; for people on active surveillance, this must have been confirmed at the time of diagnosis with no signs of spread at the time of joining the trial)
- People whose general health and ability to carry out daily activities falls within an acceptable range, as assessed by a standard medical scale (ECOG score of 0–2)
- People who have had a prostate biopsy between 1 and 6 months before joining the trial (biopsies done within the last month are not accepted, to avoid any scan interference from post-biopsy inflammation)
- People whose biopsy was done as part of initial diagnosis, a follow-up confirmation biopsy, or as part of ongoing active surveillance monitoring
- People where at least one biopsy sample was taken using MRI guidance
Who may not be able to join:
- People who have previously received any treatment for prostate cancer, including surgery, radiation therapy, brachytherapy, hormone therapy, or chemotherapy
- People who have chronic prostatitis, which includes ongoing bacterial prostate infection, chronic pelvic pain related to the prostate, or a known diagnosis of prostate inflammation without symptoms
- People who currently have an active infection in or around the prostate or lower urinary tract
- People whose bone marrow, kidneys, liver, heart, or lungs are not functioning well enough to meet the trial's requirements (confirm with trial site for specific thresholds)
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prof. Dr. Andreas Kjær, Curasight
Phone: +45 22830160
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Part 1: Standard uptake value (SUV) max at 30, 60, and 120 minutes post-injection (p.i.) - robustness; Part 2: SUVmax at 60 minutes p.i.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.